Skip to main content
  1. Right Decisions
  2. Back
  3. Dermatology pathways
  4. Melanoma
Announcements and latest updates

Right Decision Service newsletter: March 2024

Welcome to the Right Decision Service (RDS) newsletter for March 2024. Please forward this newsletter to others who may be interested. They can contact olivia.graham@nhs.scot to be added to the circulation list.

Promotion and communication resources

Promotional flyers are now available in the Learning and Support area of RDS:

What is RDS and what impact does it have? (infographic)

General RDS flyer

Being a partner in my care: Realistic medicine app for citizens

Managing medicines for patients and carers app

Home care decisions app

Child protection app (South Lanarkshire HSCP)

All except the infographic are also available as editable Word versions. Please contact his.decisionsupport@nhs.scot  if you would like Word versions.  

Redesign and improvements to RDS

Search and browse improvements are progressing well and the plan is still to release these in mid-May.  The first stages of work on archiving and version control are complete. User stories (requirements) are being defined for:

  • Deep linking to individual toolkit URLs/QR codes
  • Translating content from a structured Word document directly into RDS
  • Capability to review and edit changes made to shared content

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

A big thank you to all of you who have completed our Impact and Value questionnaire. The data from this will be really helpful in informing the first draft of the business case for long term provision of the RDS. This will be reviewed by the National Advisory Board for RDS later this month.

We welcome further responses. If you haven’t yet completed the survey, please follow this link, and please encourage other RDS toolkit leads and users to do so.

New toolkits

A few examples of toolkits published to live in the last month:

 

Toolkits in development

Some of the toolkits the RDS team are currently working on:

  • Updates to the Respiratory prescribing guidance and Manage Medicines for patients and carers toolkits
  • Respiratory Managed Clinical Network Pathways
  • Child abuse pathways in NHS Tayside
  • Patient information leaflet collection in NHS Borders
  • Referral management toolkit for NHS Borders
  • NHS Lothian – Infectious diseases; Acute oncology guidelines; Royal Infirmary of Edinburgh Emergency Care.

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Learning opportunities

The RDS Learning working group is progressing with developing training resources for editors, and intend to have resources to share by end of June. This includes resources for:

  • Each stage of the development journey for RDS toolkits – Scoping to Implementation/Evaluation and Maintenance.
  • RDS content governance.
  • Core functionality – learning bytes.

 

Editor webinars

Just a reminder that we are offering webinars for existing and potential new editors on the following dates:

  • Wednesday 10 April 3.30-4.30 pm
  • Thursday 18 April 12-1 pm

 

To book for one of these webinars, please complete the registration form at https://forms.office.com/e/eGjKqNVjeF

Quality audit

Many thanks to all of you who have met with me recently to complete or clarify your responses to the quality audit survey at the end of last year.  Work to complete the quality audit for all toolkits published on RDS prior to November last year will continue for the next few months.

Implementation projects

The RDS team is now working with Moray HSCP to evaluate impact of the new RDS toolkit “Preventing progress of diabetes”  (https://preventdiabetes.scot.nhs.uk ) to support people at high risk of diabetes type 2 and those who are candidates for remission. We are looking at the impact of use of the app with SMS prompts on people’s readiness for lifestyle change over an 8 week period. This includes comparing impact in people who have a call with a dietitian in addition to using the app to people who only use the app.

If you have any questions about the content of this newsletter, please contact us on his.decisionsupport@nhs.scot.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

 

Melanoma

Warning

Cutaneous Melanoma: A skin cancer of the melanocytes in the skin. Melanoma is the third most common skin cancer in the UK. It accounts for more cancer deaths than all other skin cancers combined. Although melanoma is more often diagnosed in older people, it is increasingly affecting younger people. It is the second most common cancer in adults aged between 25 and 49. Most melanomas occur in people with pale skin. Precursor lesions include acquired and large congenital melanocytic naevi (moles), and dysplastic naevi but at least 50% appear with no preceding lesion. Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.  

 

Please see key messages with scenarios outlining common situations where people have benign lesions that cause some concern and need additional evaluation over time. 

 

Scottish Referral Guidelines for suspected cancer are available at the following link - https://www.cancerreferral.scot.nhs.uk/Home 

Treatment/ therapy

Benign: 

Referral is not usually required for obviously benign lesions, Features which are generally reassuring and suggest a benign lesion include: 

  • Regularity of colour, surface, and border. 
  • Rapid growth over days rather than weeks – common with trauma or inflammation. 
  • 'Stuck on' appearance with keratotic plugs on the surface (suggests a seborrhoeic keratosis). 
  • A pigmented lesion in a child (melanoma is very rare in this age group). 

Risk evaluation: 

Risk evaluation indicating at risk people includes the following: 

  • A personal history of skin cancer.  
  • A family history of skin cancer.  
  • Pale skin (Fitzpatrick Skin Type I and II) that burns easily.  
  • Red, blonde or light-coloured hair. 
  • Blue or green eyes. 
  • History of sunburn, particularly blistering sunburn in childhood. 
  • A large number of moles. 
  • Unusually high sun exposure (living or spending frequent periods in hot countries). 
  • Use of tanning beds or sun beds, particularly if 10 or more sessions.  
  • Increasing age.  
  • Immunosuppression 
  • Pigmented lesions which 'stand out from the crowd' because they are different (the 'Ugly Duckling sign') are a cause for concern, especially if they are changing.  

The Weighted 7-point checklist may be used to assess pigmented skin lesions, and determine referral:  

o Major features of the lesion (2 points each): change in size, irregular shape or border, irregular colour. 

o Minor features of the lesion (1 point each): largest diameter 7 mm or more, inflammation, oozing or crusting of the lesion, change in sensation (including itch). 

o Suspicion is greater for lesions scoring 3 points or more. However, if there are strong concerns about cancer, any one feature is adequate to prompt urgent referral under Urgent Suspicion Of Cancer (USOC) arrangements.

The ABCD(E) system can also be used for pigmented lesion assessment (http://www.pcds.org.uk/clinical-guidance/melanoma-an-overview1) 

 

Refer using a Routine priority (as long as there is no index lesion of concern, where USOC needed) for risk estimation if people are at higher risk of melanoma, such as those with: 

  • Giant congenital pigmented naevi (risk is highest for those measuring 20 cm in diameter or more). 
  • A family history of 3 or more cases of melanoma and/or family history of pancreatic cancer— Those with two cases in the family may also benefit, especially if one of the cases had multiple primary melanomas or the atypical mole phenotype.  
  • More than 100 normal moles. 

Atypical moles, see: https://www.pcds.org.uk/clinical-guidance/atypical-dysplastic-melanocytic-naevus  (particularly if multiple). 

Possible malignant: 

Urgently refer (using USOC, or similar, urgent pathway) to a dermatologist, plastic surgeon, or other suitable specialist with experience of melanoma diagnosis if: 

  • The lesion is suggestive of malignant melanoma (including nodular and amelanotic melanoma). For example: 
  • Lesions scoring 3 points or more (based on major features scoring 2 points each and minor features scoring 1 point each) on the 7-point checklist. However, any one feature is adequate to prompt urgent referral. 
  • New nodules which are pigmented or vascular in appearance. 
  • Nail changes, such as a new pigmented line in the nail or pigmentation under the nail that differs from other nails. 
  • A skin condition is persistent or slowly evolving and unresponsive, with an uncertain diagnosis, and melanoma is a possibility. 
  • A biopsy has confirmed the diagnosis of malignant melanoma. Note: normally such patients would be referred prior to excision. 

A copy of the pathology report should be sent with the referral correspondence, as there may be details (such as tumour thickness, excision margin) that will specifically influence further management.

Scottish Referral Guidelines for suspected cancer are available at the following link - https://www.cancerreferral.scot.nhs.uk/Home 

Referral Management

Benign: 

Manage in primary care. Consider scenarios 1 to 3 in Key messages. Review access to alternative providers for patient access to benign lesion treatments outside the NHS. 

Risk evaluation: 

 

Possible malignant: 

Refer using the USOC pathway for skin cancer. 

 

Scottish Referral Guidelines for suspected cancer are available at the following link - https://www.cancerreferral.scot.nhs.uk/Home 

Clinical tips

  • Lesions change over time and a benign diagnosis at initial assessment may need to be reviewed if the lesion changes. Initial safety netting by check in 3 months against baseline photos is current NICE guidance for lesions with some measure of uncertainty. For itchy benign-appearing lesions causing uncertainty, see scenario 2 in Key Messages. 
  • Photography is key for monitoring of lesions, sharing the diagnostic process and helping patients self-monitor. It improves the quality of the GP record and can be used for teledermatology. See scenarios below illustrating common dilemmas 

Scenario 1  

Low suspicion of malignancy: teledermatology may be used outside the USOC process, where locally available. Include a stable non-changing clinically benign skin lesion, but where the clinical diagnosis is uncertain and doesn’t satisfy 7 point checklist. Suitable photos are essential: 

take at least 3 images of the lesion, once indicated with an inked arrow or circle, including:  

  • regional photograph with lesion indicated with ink.  
  • macro image plane and at an angle.  
  • dermoscopic image with and without gel/polarisation.  

Include core history: 

  • see Risk Evaluation: e.g. evolution, symptoms, skin type, family history, eye colour, episodes of burning, high mole count.  

Scenario 2 

For a pigmented lesion which does not satisfy criteria for referral but is difficult to evaluate, consider the following: 

  • Take a photograph (see scenario 1)  
  • Ask a senior colleague with additional expertise/dermoscopy skills.  
  • Where the lesion is itchy and suspicious for seborrhoeic keratosis take a photo, use emollient and moderate potency steroid for 3 weeks and review to ensure return to previous appearance. 

Scenario 3  

For someone with multiple pigmented lesions which appear benign but give rise to uncertainty: 

  • Highlight with ink (number and arrow) those that warrant monitoring or assessment and take regional /macro/dermoscopy photos. Suggest patient participates in self-monitoring with Apps (review NHS Apps). Failure to number them in regional photo will risk misidentification. 
  • If atypical see “risk evaluation” 

ICD search categories

Malignant 

ICD11 code - 2C30 

Editorial Information

Last reviewed: 24/05/2023

Next review date: 24/05/2025

Author(s): Adapted from the BAD Referral Guidelines.

Version: BAD 1

Co-Author(s): Publisher: Centre for Sustainable Delivery, Scottish Dermatological Society.

Approved By: Scottish Dermatological Society